Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Melissa Carpenter: making stem cells for many, safely

Barriers must be overcome to move cell therapies from the laboratory to the clinic

Melissa Carpenter runs a cell-therapy consulting business and is a senior scientific advisor to Proteus Venture Partners, an investment group focusing on regenerative medicine. She began her professional career studying neural stem cells at CytoTherapeutics Inc. and then became director of stem cell biology at Geron Corp. just weeks after the first publication about human embryonic stem cells. She worked there for five years before moving first to the Robarts Research Institute in Ontario, Canada, and then to Novocell as vice president of research and development. Monya Baker spoke with her about her work and her recent Nature Biotechnology review on developing safe therapies from human pluripotent stem cell lines1.

Related articles

Prepping stem cells for the clinic


  1. 1

    Carpenter, M. K., Frey-Vasconcells, J. & Rao, M. S. Developing safe therapies from human pluripotent stem cells Nature Biotechnol. 27, 606–613 (2009).

    CAS  Article  Google Scholar 

Download references


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Baker, M. Melissa Carpenter: making stem cells for many, safely. Nat Rep Stem Cells (2009).

Download citation


Quick links